Tablet
Latest AstraZeneca AB Patents:
- Arginase inhibitors and methods of use thereof
- Conjugates comprising cleavable linkers
- Modulators of APOL1 expression
- Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
- Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
Description
Claims
The ornamental design for a tablet, as shown and described.
Referenced Cited
U.S. Patent Documents
Other references
4439195 | March 27, 1984 | Swanson et al. |
D377086 | December 31, 1996 | Tortarolo |
D430285 | August 29, 2000 | Chen et al. |
D437407 | February 6, 2001 | Burrows |
D493518 | July 27, 2004 | McAllister et al. |
D506545 | June 21, 2005 | McAllister et al. |
7029699 | April 18, 2006 | Robinson et al. |
D564086 | March 11, 2008 | Nielsen et al. |
D601689 | October 6, 2009 | Karolak et al. |
- U.S. Appl. No. 29/356,484, filed Feb. 26, 2010.
Patent History
Patent number: D636070
Type: Grant
Filed: Feb 26, 2010
Date of Patent: Apr 12, 2011
Assignee: AstraZeneca AB (Södertälje)
Inventors: Tove Illing (Macclesfield), Johan Janner (Södertälje), Jonathan Sutch (Loughborough)
Primary Examiner: Charles A Rademaker
Attorney: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Application Number: 29/356,485
Type: Grant
Filed: Feb 26, 2010
Date of Patent: Apr 12, 2011
Assignee: AstraZeneca AB (Södertälje)
Inventors: Tove Illing (Macclesfield), Johan Janner (Södertälje), Jonathan Sutch (Loughborough)
Primary Examiner: Charles A Rademaker
Attorney: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Application Number: 29/356,485
Classifications
Current U.S. Class:
Tablet Or Caplet (1) (D24/101)